Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: JNJ stock price vs HUM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Implied fair value · at JNJ's multiple
Needs JNJ P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
Bear
$76.44
Base
$92.02
Bull
$112.30
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
JNJ vs PFE
Eli Lilly and Company
JNJ vs LLY
Abbott Laboratories
JNJ vs ABT
Amgen Inc.
JNJ vs AMGN
UNITEDHEALTH GROUP INC
JNJ vs UNH
Elevance Health, Inc.
JNJ vs ELV
CVS HEALTH Corp
JNJ vs CVS
Cigna Group
JNJ vs CI
CENTENE CORP
JNJ vs CNC
Oscar Health, Inc.
JNJ vs OSCR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe JNJ’s margin leadership and balance sheet strength will persist despite the weak Piotroski signal, then a selective long bias in JNJ makes sense because its fundamentals are materially stronger than HUM’s while the valuation gap is not supported by HUM’s lower-quality profitability profile.
On a P/E basis, JNJ trades at 23.1x versus HUM at 38.1x, while the model’s implied price for JNJ is $419.79 versus the current $254.41, suggesting a 65.0% upside under the stated multiple assumption. However, HUM-based valuation ranges are extremely wide and include a HUM implied range of $13.55 to $423.31, which reduces conviction in the point estimate.
Supporting Metrics
